Research on Crimean-Congo hemorrhagic fever virus is underway, with studies focusing on various aspects of the virus, including its glycoproteins and the potential for monoclonal antibody therapies. Some research suggests that targeting specific components of the virus, such as GP38, may help limit its spread and effects. The overall goal of this research appears to be the development of effective treatments and therapies for Crimean-Congo hemorrhagic fever.